Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)
China · Delayed Price · Currency is CNY 52.05
-2.46 (-4.51%)
Sep 11, 2026, 3:00 PM CST
Xiamen Amoytop Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 4,001 | 3,680 | 2,809 | 2,093 | 1,517 | 1,123 |
Other Revenue | 20.83 | 15.19 | 7.75 | 7.74 | 10 | 9.51 |
| 4,022 | 3,696 | 2,817 | 2,100 | 1,527 | 1,132 | |
Revenue Growth | 28.16% | 31.18% | 34.13% | 37.55% | 34.86% | 42.61% |
Cost of Revenue | 357.1 | 259.99 | 183.51 | 140.2 | 171.01 | 126.99 |
Gross Profit | 3,664 | 3,436 | 2,634 | 1,960 | 1,356 | 1,005 |
Selling, General & Admin | 1,930 | 1,815 | 1,392 | 1,060 | 841.02 | 700.65 |
Research & Development | 410.02 | 388.03 | 294.71 | 228.52 | 148.58 | 79.74 |
Other Operating Expenses | 42.43 | 18.68 | 13.3 | 10.95 | 7.64 | 5.55 |
Operating Expenses | 2,384 | 2,222 | 1,703 | 1,300 | 995.83 | 783.6 |
Operating Income | 1,280 | 1,214 | 930.33 | 659.88 | 360.06 | 221.64 |
Interest Expense | -3.49 | -1.42 | -0.45 | -0.51 | -0.62 | -1.07 |
Interest & Investment Income | 10.36 | 10.64 | 6.99 | 10.17 | 8.09 | 7.84 |
Currency Exchange Gain (Loss) | -1.42 | -0.38 | -0.12 | -1.03 | 0.48 | -0.47 |
Other Non Operating Income (Expenses) | 20.32 | -0.25 | -0.09 | -0.39 | -0.25 | -0.24 |
EBT Excluding Unusual Items | 1,306 | 1,222 | 936.67 | 668.13 | 367.77 | 227.69 |
Gain (Loss) on Sale of Investments | 3.37 | 3.45 | 0.88 | 2.65 | 0.4 | 1.8 |
Gain (Loss) on Sale of Assets | 0.47 | -0.99 | -0.03 | -0.87 | 0.03 | -1.8 |
Asset Writedown | - | - | - | -12.76 | - | - |
Other Unusual Items | -81.28 | -49.28 | -6.5 | -16.49 | -12.27 | -12.4 |
Pretax Income | 1,229 | 1,175 | 931.03 | 640.65 | 355.93 | 215.29 |
Income Tax Expense | 148.72 | 144.14 | 103.42 | 85.21 | 68.91 | 34.09 |
Net Income | 1,080 | 1,031 | 827.6 | 555.45 | 287.02 | 181.2 |
Net Income to Common | 1,080 | 1,031 | 827.6 | 555.45 | 287.02 | 181.2 |
Net Income Growth | 13.53% | 24.61% | 49.00% | 93.52% | 58.40% | 55.44% |
Shares Outstanding (Basic) | 407 | 408 | 408 | 405 | 404 | 403 |
Shares Outstanding (Diluted) | 411 | 409 | 408 | 405 | 404 | 403 |
Shares Change | 0.57% | 0.38% | 0.56% | 0.29% | 0.39% | 0.18% |
EPS (Basic) | 2.65 | 2.53 | 2.03 | 1.37 | 0.71 | 0.45 |
EPS (Diluted) | 2.63 | 2.52 | 2.03 | 1.37 | 0.71 | 0.45 |
EPS Growth | 12.89% | 24.14% | 48.18% | 92.96% | 57.78% | 55.17% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 403.04 | 473.23 | 179.28 | 223.64 | 143.99 | 43.85 |
Free Cash Flow Per Share | 0.98 | 1.16 | 0.44 | 0.55 | 0.36 | 0.11 |
Dividend Per Share | 0.620 | 0.620 | 0.620 | 0.410 | 0.213 | 0.100 |
Dividend Growth | 0% | 0% | 51.22% | 92.49% | 113.00% | 100.00% |
Gross Margin | 91.12% | 92.97% | 93.49% | 93.33% | 88.80% | 88.78% |
Operating Margin | 31.84% | 32.84% | 33.02% | 31.42% | 23.58% | 19.57% |
Profit Margin | 26.85% | 27.91% | 29.38% | 26.45% | 18.80% | 16.00% |
Free Cash Flow Margin | 10.02% | 12.80% | 6.36% | 10.65% | 9.43% | 3.87% |
EBITDA | 1,424 | 1,327 | 999.36 | 713.25 | 403.23 | 260.33 |
EBITDA Margin | 35.41% | 35.92% | 35.47% | 33.96% | 26.41% | 22.99% |
D&A For EBITDA | 143.86 | 113.79 | 69.03 | 53.37 | 43.17 | 38.69 |
EBIT | 1,280 | 1,214 | 930.33 | 659.88 | 360.06 | 221.64 |
EBIT Margin | 31.84% | 32.84% | 33.02% | 31.42% | 23.58% | 19.57% |
Effective Tax Rate | 12.11% | 12.26% | 11.11% | 13.30% | 19.36% | 15.83% |
Revenue as Reported | 4,022 | 3,696 | 2,817 | 2,100 | 1,527 | 1,132 |
Advertising Expenses | - | - | - | - | 2.94 | 5.48 |